Investor Watch Series | S2 E4 | Largest Life Sciences Fund In History. Pharma Nervous?

Jul 25, 2020 | Digital Media, Investor Watch Series, Video

TrialSite News

Welcome To Investor Watch

In this series will be going over trials, research and other clinical verticals that receive funding. Below are the ones we cover in this episode:

  • Blackstone Raises Largest Life Sciences PEG Fund in History & Already Putting Capital to Work: Should Big Pharma be Nervous? Blackstone has raised more all purpose investment funds than another other private equity group in the United States. With the closing of Blackstone Life Sciences V (“BXLS V”), this “inaugural” fund was “oversubscribed” and closed at $4.6 billion of total capital commitments. Blackstone just established itself as the king of life sciences investors. In generally hard times for many, vast pools of capital now compete for the most important clinical research breakthroughs. With this new class of competitor in drug development, should big pharma be nervous? https://trialsitenews.wpengine.com/blackst…
  • Vaccine Maker Shopping for a Country to Conduct Phase 3 Clinical Trial: Prospects Look Increasingly Dim Vaccine maker CanSino Biologics, at one point the leading vaccine developer in pursuit of a COVID-19 vaccine, continues to slip behind the competition, and recently, its co-founder and director announced the company’s discussions with various countries to conduct a Phase 3 clinical trial. While on the domestic front, the Chinese government has volunteered its military for an exclusive one year use, the reality is that COVID-19 cases have gone down in that country, where the pathogen originated from, due more than likely to lax wet market public health standards. Moreover, domestically, two other vaccines have moved into Phase 3 including Sinovac and a unit China National Pharmaceutical Group (Sinopharm), hence making the domestic field probably too crowded. Therefore, the company’s look overseas and thus far only a few countries are even willing to entertain talking to them https://trialsitenews.wpengine.com/vaccine…
  • Vanderbilt Rapidly Accelerates Research Deal Making Targeting COVID-19 Including Access to Open-Source Research Opportunity Vanderbilt researchers have pivoted a great deal of research activity toward addressing the COVID-19 pandemic. Vanderbilt’s Center for Technology Transfer & Commercialization (CTTC) has accelerated its services to facilitate three option/license agreements, 43 material transfer agreements (MTAs), and the filing of 11 patent applications in record time. In what typically takes up to nine months (complex license agreement) or up to 3 weeks for the MTA, now under the CTTS Vanderbilt is cranking deals out in as few as 10 days or 24 hours respectively. A show of dedication to directing innovation with commercial potential to the collective effort of fighting COVID-19. https://trialsitenews.wpengine.com/vanderb…
  • Investigator with the Midas Touch in Big Sky Country Raises $22m in A Round for Research Labs Dr. Jay Evans is making it rain up in Missoula, Montana: raining research money that is. TrialSite News has reported on how this exceptional individual and his team, formerly part of a GlaxoSmithKline lab in Big Sky country, transitioned to keep the research going in the area, collaboration with the University of Montana’s Center for Translational Medicine. Evans was part of the GSK lab and the University pounced on the human capital upon GSK’s departure. As part of a public-private maneuver, a spinoff called Inimmune Corp was set up to hire the GSK talent up there. In late April, the team secured a $2.5 million grant from the National Institutes of Health (NIH) and, just recently, Mr. Evans raised $22 million in Series A funding from Two Bear Capital, a new venture capital firm based in Whitefish, Montana. Dr. Evans makes good things happen. https://trialsitenews.wpengine.com/investi…

0 Comments

Pin It on Pinterest